A Deregulated Medtech Sector Could Flourish In Merz’s Industry-Friendly Germany
After Last-Minute Parliamentary Scare Chancellor Vows To Hit The Ground Running For Industry
Less bureaucracy, no more national supply chain law, framework agreements and competition for direct reimbursement of medtech innovations are among the positive changes the local medtech industry might expect as Germany’s new government gets down to work. Life sciences lawyer Gunnar Sachs offers a view from the ground.
